Filing Details

Accession Number:
0001140361-11-001841
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-01-07 12:54:47
Reporting Period:
2011-01-05
Filing Date:
2011-01-07
Accepted Time:
2011-01-07 12:54:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
707511 Regenerx Biopharmaceuticals Inc RGRX.OB Pharmaceutical Preparations (2834) 521253406
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1092601 Spa Finanziaria Tau Sigma Via Sudafrica, 20
Rome L6 00144
No No Yes No
1168857 Lda Farmaceutica Defiante 1 New York Street
New York NY 10005
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-01-05 925,926 $0.27 12,937,111 No 4 P Indirect Indirect
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect Indirect
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Warrants (right to buy) Acquisiton 2011-01-05 1 $0.00 370,370 $0.38
Common Stock Common Stock Warrants (right to buy) Disposition 2011-01-05 1 $0.00 256,148 $4.06
Common Stock Common Stock Warrants (right to buy) Acquisiton 2011-01-05 1 $0.00 256,148 $0.38
Common Stock Common Stock Warrants (right to buy) Disposition 2011-01-05 1 $0.00 333,333 $2.75
Common Stock Common Stock Warrants (right to buy) Acquisiton 2011-01-05 1 $0.00 333,333 $0.38
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1 2011-07-07 2016-01-07 No 4 J Indirect
0 2011-03-16 No 4 J Indirect
1 2011-12-31 No 4 J Indirect
0 2011-12-21 No 4 J Indirect
2 2011-12-31 No 4 J Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 984,615 Direct
Footnotes
  1. Securities directly owned by Defiante Farmaceutica S.A. ("Defiante"). Defiante is 58% directly owned by Sigma Tau Finanziaria S.p.A. ("Sigma Tau") and 42% directly owned by Sigma Tau's wholly-owned subsidiary, Sigma Tau International S.A.
  2. The Warrant was issued by the Issuer to Defiante in consideration of Defiante's purchase of Common Stock.
  3. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant became exercisable on September 16, 2006.
  4. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant became exercisable on December 21, 2006.